An update from Ibio ( (IBIO) ) is now available.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody, IBIO-600, designed for obesity and cardiometabolic disorders. This agreement involves an upfront payment of $750,000 in stock and potential milestone payments up to $28 million. The collaboration enables iBio to expand its treatment programs, leveraging its proprietary technology for developing a bispecific antibody targeting myostatin/activin A, with the aim of entering clinical trials in 2026. The initiative reflects iBio’s strategy to enhance its pipeline with advanced therapeutics that promote weight loss while preserving muscle mass.
More about Ibio
iBio, Inc. is a biotech company utilizing AI and computational biology to develop innovative biopharmaceuticals targeting cardiometabolic diseases, obesity, cancer, and other challenging medical conditions. Their approach involves combining proprietary 3D modeling with drug discovery platforms to create breakthrough antibody treatments.
Average Trading Volume: 137,996
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $22.42M
For a thorough assessment of IBIO stock, go to TipRanks’ Stock Analysis page.
